Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Neurology|December 16, 2024
Vestibular epilepsy: clinical and electroencephalographic characteristics with the proposed diagnostic criteriaMarine Perriguey, Maya Elziere, Christophe Lopez, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 27, 2020
Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?Adil Maarouf, Audrey Rico, Clemence Boutiere, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 24, 2021
Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With RituximabMarine Perriguey, Adil Maarouf, Jan-Patrick Stellmann, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 21, 2023
Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?Roxane Claverie, Marine Perriguey, Audrey Rico, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 16, 2024
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple SclerosisLisa Graille-Avy, Clemence Boutiere, Camille Rigollet, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 5, 2025
Fluorescein Angiography as a Surrogate Marker of Disease Activity in Susac SyndromeLaura Guttieres, Lea Vannelli, Sarah Demortiere, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 14, 2025
Diagnostic Utility of Kappa Free Light Chain Index in Adults With Inaugural Optic NeuritisSarah Demortiere, Natacha Stolowy, Marine Perriguey, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 5, 2025
Prevalence of hypogammaglobulinemia after non-anti-CD20 therapies and impact of switching to rituximab/ocrelizumab in multiple sclerosisMarine Perriguey, Camille Rigollet, Sean A Freeman, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 20, 2025
Extended-interval dosing of rituximab/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosisCamille Rigollet, Sean A Freeman, Marine Perriguey, et al.
Pageof 1